For the quarter ending 2025-09-30, KALV has $339,931K in assets. $322,932K in debts. $243,497K in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-07-31 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 243,497 | 124,304 | ||
| Marketable securities | 65,661 | 67,161 | ||
| Accounts receivable, net | 5,779 | 1,926 | ||
| Inventory | 458 | - | ||
| Research and development tax credit receivable | 1,343 | 561 | ||
| Prepaid expenses and other current assets | 8,488 | 11,944 | ||
| Total current assets | 325,226 | 205,896 | ||
| Property and equipment, net | 3,190 | 2,067 | ||
| Right of use assets | 9,096 | 5,165 | ||
| Other assets | 2,419 | 2,377 | ||
| Total assets | 339,931 | 215,505 | ||
| Accounts payable | 8,074 | 5,869 | ||
| Accrued expenses | 20,767 | 18,971 | ||
| Deferred revenue | 11,512 | 11,413 | ||
| Lease liability - current portion | 1,429 | 2,122 | ||
| Royalty obligation - current portion | 3,287 | - | ||
| Total current liabilities | 45,069 | 38,375 | ||
| Lease liability - net of current portion | 9,128 | 4,019 | ||
| Royalty obligation - net of current portion | 129,707 | - | ||
| Royalty obligation | - | 132,321 | ||
| Convertible notes | 139,028 | - | ||
| Total long-term liabilities | - | 136,340 | ||
| Total liabilities | 322,932 | - | ||
| Common stock, 0.001 par value 100,000,000 shares authorized at september 30, 2025 and december 31, 2024 50,542,711 and 49,433,611 shares issued and outstanding at september 30, 2025 and december 31, 2024, respectively | 50 | 50 | ||
| Additional paid-in capital | 762,776 | 760,393 | ||
| Accumulated deficit | -739,098 | -713,266 | ||
| Accumulated other comprehensive loss | -6,729 | -6,387 | ||
| Total stockholders equity | 16,999 | 40,790 | ||
| Total liabilities and stockholders equity | 339,931 | 215,505 | ||
KalVista Pharmaceuticals, Inc. (KALV)
KalVista Pharmaceuticals, Inc. (KALV)